Researchers from UC Davis have been studying six offspring of a genome-edited dairy bull that had been altered to prevent it from growing horns. Now, they report that none of the calves, which are the first reported offspring of a genome-edited bull, developed horns and blood work and physical exams of the calves found them all to be healthy.
At the SynBioBeta 2019 conference in San Francisco, Inscripta launched the Onyx—a fully automated benchtop instrument for genome-scale engineering. The CRISPR-mediated, massively parallel platform—which includes software, consumables, instrument, and assays enables researchers to engineer microbial libraries containing the full breadth and scope of possible edit types, in their own labs.
Adeno-associated virus (AAV) is already gene therapy’s delivery vehicle of choice. And now, more efficient AAVs are being engineered using directed evolution and AI-guided workflows.
On what would have been her 99th birthday, we can think of no better way to honor Rosalind Franklin than by highlighting the winner of the Rosalind Franklin Award for Leadership in Industrial Biotechnology given out by the Rosalind Franklin Society. This year, the award went to Reshma Shetty, PhD, a co-founder of Ginkgo Bioworks and a trailblazer in the field of synthetic biology.
Although antiretroviral therapy has turned HIV into a chronic disease, a cure has eluded virologists. New research shows that a combination of long-acting slow-effective release antiviral therapy (LASER ART) and CRISPR-Cas9 successfully eliminated HIV from infected humanized mice. Although an interesting step forward, the road to a cure for HIV in humans is a long one with much more work to be done.
Inscripta offered a peek into their progress toward making “the world’s first scalable platform for benchtop digital genome engineering" at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference.
High-throughput assays developed at the Broad Institute have identified the first small-molecule inhibitors of a CRISPR-Cas9 nuclease. This work will not only lead to more precise control of genome editing technology, but lays the foundation for further study of these “anti-CRISPR” molecules.
A concern that has plagued CRISPR-Cas9 technology from the beginning is the possibility, and unknown effect, of off-target effects—DNA mutations that result from CRISPR-Cas9...
In a first for patients born with the deadly X-SCID immunodeficiency disease, in which immune cells do not develop or function normally, a safe and effective gene therapy has provided a cure. The eight babies involved in the study have functioning immune systems, normal growth, and are busy toddlers able to explore their surroundings.
This is an exciting time for the field of gene therapy. It feels as if there is a renaissance underway following a difficult two decades when the community had to retrench, learning and recovering from the tragic setbacks in clinical trials in the United States and France.